Women who received risedronate and alendronate were followed up for a mean of 226 and 238 days on therapy, respectively. At baseline, a greater proportion of the risedronate cohort had risk ...

Risedronate Medication Information Learn everything you need to know about Risedronate-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it.

Risedronate decreases bone resorption and turnover, and has been used effectively for the treatment of postmenopausal and corticosteroid-induced osteoporosis and Paget's disease.

Risedronate is the latest of the bisphosphonates to be used for the management of resorptive bone disease. Clinical improvements, assessed by the incidence of fracture and changes in bone mineral ...

Risedronate, a powerful bisphosphonate that inhibits bone breakdown and slow bone removal, is garnering attention as a treatment for osteoporosis. Find out more in this easy-to-navigate collection ...

Adults prescribed risedronate who discontinued use for 1 year had a higher risk for mortality than adults who continued treatment (HR = 1.66; 95% CI, 1.01-2.73).

In the Results section, under Comparisons of Treatment and Cancer Therapy Groups, the P-value was given as P.5 in the first sentence of the third paragraph, whereas it should have been P.05, as ...

Risedronate has a possibility to interact with more drugs. These interactions are harmful. Drug interactions can be prevented by avoiding unwanted drug combinations.

Risedronate GR is an oral bisphosphonate which has flexible administration requirements for patients. 6 Due to its gastro-resistant enteric coating risedronate GR can bypass the stomach and is ...

Risedronate did not prevent bone loss in premenopausal women with breast cancer who were undergoing adjuvant chemotherapy, according to new phase-3 trial data. Data from a trial conducted by ...

The Overall Osteoporosis Drug Market Will Be Mostly Flat, With Sales Remaining Just Over $6.2 Billion from 2010 to 2020, According to Findings from Decision Resources BURLINGTON, Mass.-- (BUSINESS ...